ShockWave Medical, Inc. (SWAV)
Stock Price:
$72.22 USD
-0.13 (-0.18%)
Updated Oct 27, 2020 12:18 PM EDT - Market open
Key Info
| Market Cap |
2.46B |
| Revenue (ttm) |
51.13M |
| Net Income (ttm) |
-64.60M |
| Shares Out |
34.00M |
| EPS (ttm) |
-2.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$72.22 |
| Previous Close |
$72.35 |
| Change ($) |
-0.13 |
| Change (%) |
-0.18% |
| Day's Open |
71.89 |
| Day's Range |
71.28 - 73.73 |
| Day's Volume |
87,906 |
| 52-Week Range |
22.01 - 79.74 |
More Stats
| Market Cap |
2.46B |
| Enterprise Value |
2.25B |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.00M |
| Float |
28.14M |
| EPS (basic) |
-2.04 |
| EPS (diluted) |
-2.12 |
| FCF / Share |
-2.40 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.59M |
| Short Ratio |
4.24 |
| Short % of Float |
9.22% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
48.03 |
| PB Ratio |
9.92 |
| Revenue |
51.13M |
| Operating Income |
-65.42M |
| Net Income |
-64.60M |
| Free Cash Flow |
-77.11M |
| Net Cash |
207.22M |
| Net Cash / Share |
6.09 |
| Gross Margin |
50.40% |
| Operating Margin |
-127.95% |
| Profit Margin |
-126.30% |
| FCF Margin |
-150.81% |
| ROA |
-18.83% |
| ROE |
-35.41% |
| ROIC |
-69.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
4 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$83.60*
(15.76% upside)
Low
72.0
Current: $72.22
High
90.0
Target: 83.60
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 42.93 | 12.26 | 1.72 |
| Revenue Growth | 250.05% | 613.38% | - |
| Gross Profit | 25.77 | 5.01 | -1.12 |
| Operating Income | -51.84 | -41.20 | -30.87 |
| Net Income | -51.11 | -41.10 | -30.62 |
| Shares Outstanding | 23.90 | 1.76 | 1.55 |
| Earnings Per Share | -2.14 | -23.39 | -19.71 |
| Operating Cash Flow | -48.11 | -41.47 | -30.35 |
| Capital Expenditures | -3.82 | -1.98 | -0.43 |
| Free Cash Flow | -51.92 | -43.45 | -30.77 |
| Cash & Equivalents | 195 | 39.64 | 53.73 |
| Total Debt | 21.94 | 15.05 | - |
| Net Cash / Debt | 173 | 24.59 | 53.73 |
| Assets | 232 | 53.42 | 59.30 |
| Liabilities | 39.29 | 23.20 | 5.13 |
| Book Value | 193 | -123 | -83.29 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ShockWave Medical, Inc. |
| Country |
United States |
| Employees |
284 |
| CEO |
Douglas Evan Godshall |
Stock Information
| Ticker Symbol |
SWAV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: SWAV |
| IPO Date |
March 7, 2019 |
Description
ShockWave Medical, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.